ABOUT FRANCE BIOLEAD
France BioLead, the French biomanufacturing sector, brings together all the players of French biomanufacturing, including manufacturers (pharmaceutical and biotechnology companies, CDMOs, CROs, equipment manufacturers, suppliers of technological solutions and consumables), academic research, training providers, the French government and competitive clusters, associations and professional unions.
Its ambition is to structure and manage a unique French biomanufacturing industry with the support of the French government, to make France a leader in biomanufacturing in Europe.
France BioLead was officially launched in December 2022, in the presence of Roland Lescure, Minister Delegate in charge of Industry, with the support of François Braun, Minister of Health and Prevention and Sylvie Retailleau, Minister of Higher Education and Research, as well as its 15 founding members, players in all biomanufacturing value chains: Alliance Innovation Santé Nouvelle-Aquitaine (ALLIS-NA), Capgemini, CEA, Clean Biologics, Enosis Santé (BioValley France, Eurobiomed, Lyonbiopôle Auvergne-Rhône-Alpes and Medicen Paris Region), France Biotech, Genopole, GTP Bioways, Inserm, Leem, Merck, Polepharma, Sanofi, Servier, Thermo Fisher Scientific.
THE FRENCH BIOMANUFACTURING SECTOR
Over the past two decades, the pharmaceutical industry has undergone a veritable revolution with the arrival of biotechnology-derived drugs, or biomedicines, which have added to our arsenal of therapeutic solutions.
What is a biomedicine? It is a drug whose active ingredient is derived from biological material, itself derived from living organisms: cells, tissues or organisms. There are different types of biomedicines: gene therapies, cell therapies, monoclonal antibodies and recombinant proteins.
These drugs have become indispensable, monoclonal antibodies now treat cancers that were incurable just a few years ago, and gene therapy makes it possible to intervene at the heart of the living machinery by repairing our genes or by strengthening our immune cells to enable them to better fight and contain cancerous cells.
Biotechnologies, which are at the source of these innovations, are the source of many hopes that are being transformed into therapeutic successes for nearly 20 million patients in France and around the world.
FRANCE BIOLEAD, THE CATALYST FOR FRENCH BIOMANUFACTURING PLAYERS
Over the past twenty years, the healthcare industry and patients have experienced a real revolution with the arrival of drugs whose active ingredients are produced from living organisms.
The mission of France BioLead:
to structure, manage, support, lead and promote the French biomanufacturing industry and its
actors
BIOMEDICINE,
THE FUTURE OF HEALTH
Now indispensable, biomedicines are not only a complement to our arsenal of chemical therapeutic solutions, but also open up new hopes for many diseases. These treatments are therefore a major public health issue.
More than 10 million people in France are affected by one of these diseases
FRENCH BIOPRODUCTION,
A DELAY TODAY,
A STEP AHEAD TOMORROW
France has an abundance of assets to find and develop the therapeutic solutions of tomorrow. Together, we must now do everything possible to reveal and activate them.
Together, let's make France a leader in the production of biomedicines by 2030
France Biolead,
the French biomanufacturing association
2-10, rue d'Oradour-sur-Glane
75015 Paris
Find us also on: